| 发明名称 | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics | ||
| 摘要 | Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic. | ||
| 申请公布号 | US9539264(B2) | 申请公布日期 | 2017.01.10 |
| 申请号 | US201514710746 | 申请日期 | 2015.05.13 |
| 申请人 | Wisconsin Alumni Research Foundation | 发明人 | DeLuca Hector F.;Plum Lori A.;Clagett-Dame Margaret |
| 分类号 | A61K31/59;A61K31/593;A61K45/06 | 主分类号 | A61K31/59 |
| 代理机构 | Andrus Intellectual Property Law, LLP | 代理人 | Andrus Intellectual Property Law, LLP |
| 主权项 | 1. A method of treating secondary hyperparathyroidism or the symptoms thereof in a subject having secondary hyperparathyroidism or at risk for developing secondary hyperparathyroidism, wherein the subject previously was administered a calcimimetic to treat the secondary hyperparathyroidism, the method comprising administering a therapeutically effective amount of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 or a pharmaceutically acceptable salt thereof to the subject wherein secondary hyperparathyroidism or the symptoms thereof are treated. | ||
| 地址 | Madison WI US | ||